Zobrazeno 1 - 10
of 10
pro vyhledávání: '"José Pablo, Maroto Rey"'
Autor:
Cristina Suarez, Alvaro Pinto, Jorge A. Garcia, Enrique Gallardo, María José Méndez-Vidal, Enrique Grande, Javier Puente, Emilio Esteban, José Pablo Maroto Rey, Jose Angel Arranz, Enrique Gonzalez-Billalabeitia, Aranzazu Gonzalez del Alba, Josep M. Piulats, Begoña Perez-Valderrama, Nuria Lainez, Martín Lázaro-Quintela
Publikováno v:
Critical Reviews in Oncology/Hematology. 113:171-190
Updated information published up to 2016 regarding major advances in renal cancer, bladder cancer, and prostate cancer is here presented. Based on an ever better understanding of the genetic and molecular alterations that govern the initial pathogeni
Autor:
Jose Carlos Villa Guzman, Rosa Garcia Marrero, José Luis González Larriba, Iciar Garcia Carbonero, Enrique Gallardo Diaz, Javier Luis Puertas Alvarez, Sara Perez Ramirez, Guillermo Velasco, Eva Fernandez Parra, Miguel Angel Climent, Maria Jose Miranda Pallares, José Pablo Maroto Rey, Rocío García Domínguez, Alvaro Pinto, Jose Angel Arranz Arija, Pablo Borrega, Guillermo Crespo, Constanza Maximiano, Cristina Suarez, Andres Meana Garcia
Publikováno v:
Journal of Clinical Oncology. 36:623-623
623 Background: Treatment of mRC is not affected by gender, studying possible differences in a real-world study, could increase the knowledge of toxicity and possible prognostic factors. Methods: SPAZO2 (NCT03091465) was a retrospective real-world st
Autor:
Miguel Martín Jiménez, Antonio Rueda Domínguez, Eduardo Díaz Rubio García, Rocío García Carbonero, José Ignacio Mayordomo Cámara, Luis G. Paz-Ares Rodríguez, Ana María Casas Fernández de Tejerina, Manuel Constenla Figueiras, José Gómez Codina, Alfredo Carrato Mena, Ana Lluch Hernández, José Pablo Maroto Rey, Pedro Pérez Segura, Álvaro Rodríguez Lescure, José Andrés Moreno Nogueira
Publikováno v:
Clinical and Translational Oncology. 11:446-454
Neutropenia is a common complication of cancer chemotherapy. Colony-stimulating factors (CSF) may be used to avoid neutropenia-associated complications. The Spanish Society of Medical Oncology (SEOM) recently constituted a working group to review the
Publikováno v:
Archivos espanoles de urologia. 66(5)
There has been expansion of therapeutic options in the management of metastatic renal cell carcinoma due to a better knowledge of the molecular biology of kidney cancers. There are different tumors grouped under the term renal cell carcinoma, being c
Autor:
Ignacio Duran, Enrique Gallardo Diaz, Albert Font, Begoña Perez-Valderrama, M. Pilar Lopez Criado, Raquel Luque, Alvaro Pinto, Martin Lázaro Quintela, Núria Sala, Carmen Santander, María José Méndez-Vidal, Esther Noguerón, Xavier Garcia del Muro, José Pablo Maroto Rey, Jose Angel Arranz, M Isabel Sáez, Miguel Angel Climent, Aranzazu Gonzalez del Alba, Nuria Lainez, Sergio Vazquez-Estevez
Publikováno v:
Journal of Clinical Oncology. 33:e15537-e15537
e15537 Background: No standard regimen exists for second line treatment of mTCC patients. Taxanes have shown some activity in this setting. Cbz, is a novel semi-synthetic taxane never tested before...
Autor:
Enrique Gonzalez-Billalabeitia, Javier Puente, Miguel Angel Climent, José Pablo Maroto Rey, Nuria Lainez, Sergio Vazquez-Estevez, María José Méndez-Vidal, Xavier Garcia del Muro, Juan Francisco Rodriguez-Moreno
Publikováno v:
Journal of Clinical Oncology. 33:TPS4584-TPS4584
TPS4584 Background: Metastatic or locally advanced squamous penile carcinoma (MLASPC) is an infrequent disease, with extremely bad prognosis. Platinum based chemotherapy is the most active treatmen...
Autor:
Maria Isabel Luengo, Sara Fernandez Arrojo, Claudia Valverde, Josep Guma, Francisco Ayala, Antonio J. Fernández, Alfonso Sanchez Munoz, Begoña Mellado, Jorge Aparicio, Jose R. Germa-Lluch, Javier Sastre, Daniel Castellano, Ignacio Duran, David Hervás, José Pablo Maroto Rey, Alberto Carmona Bayonas, Silverio Ros, Mireia Margeli, A. Saenz, Enrique Gonzalez-Billalabeitia
Publikováno v:
Journal of Clinical Oncology. 33:4536-4536
4536 Background: To evaluate the incremental prognostic value of thromboembolic events (TEE) in combination with the International Germ Cell Cancer Collaborative Group (IGCCCG). Methods: Patients w...
Autor:
Aranzazu Gonzalez del Alba, Carmen Santander, Begoña Mellado, Alfredo Sanchez, María José Méndez-Vidal, Ignacio Duran, Albert Font, Miguel Angel Climent, Martin Lázaro Quintela, José Pablo Maroto Rey, Emilio Esteban, Jose Angel Arranz Arija, Daniel Castellano, M Isabel Sáez, Enrique Grande, Javier Puente, Javier Cassinello
Publikováno v:
Journal of Clinical Oncology. 32:TPS5096-TPS5096
TPS5096 Background: Docetaxel (D) is the standard treatment for symptomatic or aggressive disease in mCRPC patients. Abiraterone acetate (AA), a specific inhibitor of CYP17, blocks persistent extra...
Autor:
Ana Ruiz Echevarria, José Pablo Maroto Rey, Ana Virgili, Estela Moreno, Emilio Esteban, Alfonso Gomez De Liano Lista
Publikováno v:
Journal of Clinical Oncology. 32:e16082-e16082
e16082 Background: Enzalutamide has proved activity in second line setting after progression to docetaxel-based chemotherapy in patients with mCRPC in a phase III trial compared to placebo. Objecti...
Autor:
Claudia Weiss, Paul Nathan, Viktor Gruenwald, José Pablo Maroto Rey, Cezary Szczylik, Camillo Porta, Sergio Bracarda, Agnese Cattaneo, Bernard Escudier, Sylvie Negrier
Publikováno v:
Journal of Clinical Oncology. 32:410-410
410 Background: Prospectively collected data evaluating therapy for papillary mRCC are limited. RAPTOR (NCT00688753) evaluated the efficacy and safety of EVE as first-line therapy for papillary mRCC. Methods: Eligible pts had histologically confirmed